A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

Mollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, H.Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy, Fan, Helen Mar and Gill, Devinder S. (2012) A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. British Journal of Haematology, 157 6: 766-769.

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Mollee, Peter
Tiley, Campbell
Cunningham, Ilona
Moore, John
Prince, H.Miles
Cannell, Paul
Gibbons, Steve
Tate, Jill
Paul, Sanjoy
Fan, Helen Mar
Gill, Devinder S.
Title A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis
Journal name British Journal of Haematology  (ERA 2012 Listed)    (ERA 2010 Rank A)   Check publisher's open access policy
Publication date 2012-06
Sub-type Article
DOI 10.1111/j.1365-2141.2012.09080.x
Volume number 157
Issue number 6
ISSN 0007-1048; 1365-2141
Start page 766
End page 769
Total pages 4
Place of publication Oxford, United Kingdom
Publisher Wiley-Blackwell Publishing
Collection year 2013
Language eng
Keyword AL amyloidosis
Intravenous melphalan
Autologous stem cell transplantation
Brain natriuretic peptide
Toxicity
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article first published online: 6 March 2012.

Document type: Journal Article
Sub-type: Article
Collections: Official 2013 Collection
Admin Only - School of Medicine
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Access Statistics: 37 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 25 Jun 2012, 10:03:53 EST by System User on behalf of School of Medicine